<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613467</url>
  </required_header>
  <id_info>
    <org_study_id>W-TONG06</org_study_id>
    <nct_id>NCT03613467</nct_id>
  </id_info>
  <brief_title>Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients</brief_title>
  <official_title>Vedio-assisted Thoracoscopic Lobectomy vs Open Lobectomy for Patients With Surgically Resectable Pathologic N2 NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LinkDoc Technology (Beijing) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tang-Du Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study was designed to compare the safety and effectiveness of vedio-assisted
      thoracoscopic lobectomy with open lobectomy for patients with surgically resectable
      pathologic N2 non-small cell lung cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The is a multi-center retrospective study. Patients with pathologic N2 NSCLC who underwent
      VATS or open lobectomy between 2014 and 2017 were included into this study. Clinical data on
      patient demographic, clinical characteristics, treatment and clinical outcomes will be
      collected to evaluate the safety and effectiveness of video-assisted thoracoscopic lobectomy
      for pathologic N2 NSCLC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 4, 2018</start_date>
  <completion_date type="Actual">July 6, 2018</completion_date>
  <primary_completion_date type="Actual">July 4, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2014-2018</time_frame>
    <description>Overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay [Perioperative outcomes]</measure>
    <time_frame>2014-2017</time_frame>
    <description>Duration of hospital stay [Perioperative outcomes]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative 30 and 90 days [Perioperative outcomes]</measure>
    <time_frame>2014-2017</time_frame>
    <description>Postoperative 30 and 90 days [Perioperative outcomes]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drainage time [Perioperative outcomes]</measure>
    <time_frame>2014-2017</time_frame>
    <description>Drainage time [Perioperative outcomes]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss [Perioperative outcomes]</measure>
    <time_frame>2014-2017</time_frame>
    <description>Intraoperative blood loss [Perioperative outcomes]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications [Perioperative outcomes]</measure>
    <time_frame>2014-2017</time_frame>
    <description>Postoperative complications [Perioperative outcomes]</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survivals in the subgroups stratified by T staging</measure>
    <time_frame>2014-2018</time_frame>
    <description>Overall survivals in the subgroups stratified by T staging</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survivals in the subgroups stratified by neoadjuvant therapy</measure>
    <time_frame>2014-2018</time_frame>
    <description>Overall survivals in the subgroups stratified by neoadjuvant therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survivals in the subgroups stratified by number of lymph node station involved</measure>
    <time_frame>2014-2018</time_frame>
    <description>Overall survivals in the subgroups stratified by number of lymph node station involved</description>
  </other_outcome>
  <other_outcome>
    <measure>Impact factors for overall survival</measure>
    <time_frame>2014-2018</time_frame>
    <description>Impact factors for overall survival</description>
  </other_outcome>
  <other_outcome>
    <measure>Impact factors for postoperative mortality within 30/90 days</measure>
    <time_frame>2014-2017</time_frame>
    <description>Impact factors for postoperative mortality within 30/90 days</description>
  </other_outcome>
  <other_outcome>
    <measure>Propensity score matching analysis of overall survival</measure>
    <time_frame>2014-2018</time_frame>
    <description>Propensity score matching analysis of overall survival</description>
  </other_outcome>
  <other_outcome>
    <measure>Propensity score matching analysis of perioperative outcomes</measure>
    <time_frame>2014-2018</time_frame>
    <description>Propensity score matching analysis of perioperative outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Propensity score matching analysis of impact factors for overall survival</measure>
    <time_frame>2014-2018</time_frame>
    <description>Propensity score matching analysis of impact factors for overall survival</description>
  </other_outcome>
  <other_outcome>
    <measure>Propensity score matching analysis of impact factors for postoperative mortality within 30/90 days</measure>
    <time_frame>2014-2018</time_frame>
    <description>Propensity score matching analysis of impact factors for postoperative mortality within 30/90 days</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2145</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>VATS lobectomy</arm_group_label>
    <description>Pathologic N2 NSCLC patients who received lobectomy by video-assisted thoracoscopic surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thoracotomy lobectomy</arm_group_label>
    <description>Pathologic N2 NSCLC patients who received lobectomy by thoracotomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>VATS lobectomy</intervention_name>
    <description>Patients who received lobectomy by video-assisted thoracoscopic surgery</description>
    <arm_group_label>VATS lobectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracotomy lobectomy</intervention_name>
    <description>Patients who received lobectomy by thoracotomy</description>
    <arm_group_label>Thoracotomy lobectomy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pathologically diagnosed N2 non-small cell lung cancer who received VATS or thoracotomy
        lobectomy between 2014 and 2017
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with age &gt; 18 years old;

          -  Patients with pathologically diagnosed non-small cell lung cancer;

          -  Patients underwent lobectomy by either VATS or thoracotomy between 2014 and 2017;

          -  Patients who received lymphadenectomy for all accessible lymph nodes;

          -  Patients with N2 lymph nodes (+) after surgeries;

        Exclusion Criteria:

          -  Patients with second primary tumors or multiple primary tumors;

          -  Patients who received chest surgeries before hospitalization;

          -  Patients with superior pulmonary sulcus tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaofei Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tang-Du Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Affiliated to Huazhong Technology Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu cancer hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xi'an Tangdu Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huaxi Hospital Affiliated to Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Chest Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital Affiliated to Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tang-Du Hospital</investigator_affiliation>
    <investigator_full_name>lixiaofei</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Vedio-assisted thoracoscopic lobectomy</keyword>
  <keyword>Thoracotomy lobectomy</keyword>
  <keyword>Real-world evidences;</keyword>
  <keyword>pN2 NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

